Gene expression of TWEAK/Fn14 and IP-10/CXCR3 in glomerulus and tubulointerstitium of patients with lupus nephritis

Nephrology

Volumn 16, Issue 4, 2011, Pages 426-432

  Lu, Jianxin ^a   Kwan, Bonnie Ching Ha ^a   Lai, Fernand Mac Moune ^a   Choi, Paul Cheung Lung ^a   Tam, Lai Shan ^a   Li, Edmund Kwok Ming ^a   Chow, Kai Ming ^a   Wang, Gang ^a   Li, Philip Kam Tao ^a   Szeto, Cheuk Chun ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

cytokine; immunology; lupus nephritis

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; CREATININE; CYTOKINE; MESSENGER RNA; PROTEIN FN14; TUMOUR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; GENE EXPRESSION; GLOMERULUS; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY TUBULE; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEINURIA;

ADULT; AGED; BIOLOGICAL MARKERS; CHEMOKINE CXCL10; CREATININE; FEMALE; GENE EXPRESSION REGULATION; HONG KONG; HUMANS; KIDNEY GLOMERULUS; KIDNEY TUBULES; LUPUS NEPHRITIS; MALE; MIDDLE AGED; PROTEINURIA; RECEPTORS, CXCR3; RECEPTORS, TUMOR NECROSIS FACTOR; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTORS;

EID: 79955369269     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2011.01449.x     Document Type: Article

References (25)

1. Lauwerys B, Houssiau F,. Cytokines: Clues to the pathogenesis of SLE. Lupus 1998; 7: 211-3. (Pubitemid 28263997)
2. Karonitsch T, Feierl E, Steiner CW, et al,. Activation of the interferon-gamma signaling pathway in systemic lupus erythematosus peripheral blood mononuclear cells. Arthritis Rheum. 2009; 60: 1463-71.
3. Lee H, Mima T, Sugino H, et al,. Interactions among type I and type II interferon, tumor necrosis factor, and beta-estradiol in the regulation of immune response-related gene expressions in systemic lupus erythematosus. Arthritis Res. Ther. 2009; 11: R1.
4. Chicheportiche Y, Chicheportiche R, Sizing I, et al,. Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: Blocking and enhancing effects of anti-TWEAK monoclonal antibodies. Arthritis Res. 2002; 4: 126-33. (Pubitemid 34257346)
5. Nakayama M, Ishidoh K, Kojima Y, et al,. Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death. J. Immunol. 2003; 170: 341-8. (Pubitemid 36026158)
6. Jakubowski A, Browning B, Lukashev M, et al,. Dual role for TWEAK in angiogenic regulation. J. Cell Sci. 2002; 115: 267-74. (Pubitemid 34145176)
7. Burkly L, Michaelson J, Hahm K, Jakubowski A, TWEA ZTS,. King tissue remodeling by a multifunctional cytokine: Role of TWEAK/Fn14 pathway in health and disease. Cytokine 2007; 40: 1-16. (Pubitemid 350088500)
8. Lee E, Lee Z, Song Y,. CXCL10 and autoimmune diseases. Autoimmun. Rev. 2009; 8: 379-83.
9. Gao H, Campbell S, Burkly LC, et al,. TNF-like weak inducer of apoptosis (TWEAK) induces inflammatory and proliferative effects in human kidney cells. Cytokine 2009; 46: 24-35.
10. Zhao Z, Burkly L, Campbell S, et al,. TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versus-host model of systemic lupus erythematosus. J. Immunol. 2007; 179: 7949-58.
11. Schwartz N, Su L, Burkly LC, et al,. Urinary TWEAK and the activity of lupus nephritis. J. Autoimmun. 2006; 27: 242-50. (Pubitemid 46206104)
12. Schwartz N, Rubinstein T, Burkly LC, et al,. Urinary TWEAK as a biomarker of lupus nephritis: A multicenter cohort study. Arthritis Res. Ther. 2009; 11: R143.
13. Hochberg M,. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997; 40: 1725.
14. Bombardier C, Gladman D, Urowitz MB, Caron D, Chang CH,. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992; 35: 630-40.
15. Weening J, D'Agati V, Schwartz MM, et al,. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004; 65: 521-30. (Pubitemid 38130646)
16. Chan RW, Lai FM, Li EK, et al,. Intra-renal cytokine gene expression in lupus nephritis. Ann. Rheum. Dis. 2007; 66: 886-92. (Pubitemid 46999788)
17. Wang G, Lai FM, Lai KB, et al,. Discrepancy between intra-renal messenger RNA and protein expression of ACE and ACE2 in human diabetic nephropathy. Am. J. Nephrol. 2008; 29: 524-31.
18. Chan RW, Lai FM, Li EK, et al,. Expression of chemokine and fibrosing factor messenger RNA in the urinary sediment of patients with lupus nephritis. Arthritis. Rheum. 2004; 50: 2882-90. (Pubitemid 39209526)
19. Leng RX, Pan HF, Qin WZ, et al,. TWEAK as a target for therapy in systemic lupus erythematosus. Mol. Biol. Rep. 2011; 38: 587-92.
20. Winkles J,. The TWEAK-Fn14 cytokine-receptor axis: Discovery, biology and therapeutic targeting. Nat. Rev. Drug Discov. 2008; 7: 411-25. (Pubitemid 351619113)
21. Narumi S, Takeuchi T, Kobayashi Y, Konishi K,. Serum levels of IFN-inducible protein-10 relating to the activity of systemic lupus erythematosus. Cytokine 2000; 12: 1561-5.
22. Lit LC, Wong CK, Tam LS, Li EK, Lam CW,. Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 2006; 65: 209-15. (Pubitemid 43131995)
23. Kong KO, Tan AW, Thong BY, et al,. Enhanced expression of interferon-inducible protein-10 correlates with disease activity and clinical manifestations in systemic lupus erythematosus. Clin. Exp. Immunol. 2009; 156: 134-40.
24. Avihingsanon Y, Phumesin P, Benjachat T, et al,. Measurement of urinary chemokine and growth factor messenger RNAs: A noninvasive monitoring in lupus nephritis. Kidney Int. 2006; 69: 747-53. (Pubitemid 43237645)
25. Segerer S, Banas B, Wörnle M, et al,. CXCR3 is involved in tubulointerstitial injury in human glomerulonephritis. Am. J. Pathol. 2004; 164: 635-49. (Pubitemid 38364678)